News of Note—BioLineRx financing; Ablynx fast track; Ophthotech pivot; Dynavax briefing documents


> BioLineRx secured a $9.6 million investment from its largest shareholder. The Novartis-partnered biotech raised the money from BVF Partners to fund clinical development. Release

> The FDA awarded fast-track status to Ablynx’s caplacizumab in acquired thrombotic thrombocytopenic purpura. Ablynx is planning to file for FDA approval of the anti-von Willebrand factor single-domain antibody next year. The fast-track nod means caplacizumab is eligible for priority review by the regulator. Statement

> Ophthotech pivoted into rare diseases. The biotech plans to test C5 complement inhibitor Zimura in Stargardt disease. Ophthotech’s interest in testing the drug in rare diseases follows setbacks to its ambition to treat age-related retinal conditions. Release


Like this story? Subscribe to FierceBiotech!

Biopharma is a fast-growing world where big ideas come along every day. Our subscribers rely on FierceBiotech as their must-read source for the latest news, analysis and data in the world of biotech and pharma R&D. Sign up today to get biotech news and updates delivered to your inbox and read on the go.

> The FDA has published the briefing documents for an advisory committee meeting about Dynavax’s hepatitis B vaccine. Documents (PDF)

Suggested Articles

By employing heart rate signals, physical activity and sleep quality, common Fitbit trackers may be able to predict the spread of the flu.

Nanox has raised $26 million to help fuel the development and commercialization of its "Star Trek"-inspired digital X-ray bed.

Oncology is clearly a major medical and societal issue, but one that sees too much focus from biopharmas at the expense of other killers.